George Wilding, MD | Authors

Will Current Clinical Trials Answer the Most Important Questions About Prostate Adenocarcinoma?

August 01, 1997

Outlined in the article by Thompson and Seay are a series of questions relevant to the spectrum of stages of prostate cancer ranging from prevention to the treatment of advanced disease. Given the prevalence of prostate cancer, the morbidity of the disease, and the death rate from prostate cancer of more than 40,000 men in the United States each year, these questions warrant answers as soon as possible.